Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ibrutinib in early stage CLL: Genetic risk factors and treatment outcome in the GCLLSG CLL12 trial.

Bloodยท2026
Same author

IGLV3-21<sup>R110</sup> and ibrutinib treatment: Results from the double-blind, randomized, placebo-controlled GCLLSG CLL12 trial in early-stage CLL.

HemaSphereยท2026
Same author

PLCG2 Exon-Skipped Variants: Insights into Their Potential Role in Chronic Lymphocytic Leukemia.

Blood advancesยท2026
Same author

Chronic lymphocytic leukemia with <i>IGH</i>::<i>BCL3</i>-translocation is characterized by a homogeneous and distinct genetic and epigenetic landscape.

HemaSphereยท2026
Same author

The spectrum of immunoglobulin heavy chain enhancer hijacking in chronic lymphocytic leukemia.

Leukemiaยท2026
Same author

Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcomes analysis of the CLL13/GAIA trial.

Bloodยท2026

Related Experiment Video

Updated: Apr 25, 2026

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

23.7K

Advances in treating chronic lymphocytic leukemia.

Eugen Tausch1, Daniel Mertens2, Stephan Stilgenbauer1

  • 1Ulm University, Department of Internal Medicine III Albert-Einstein-Allee 23, 89081 Ulm Germany.

F1000Prime Reports
|August 29, 2014
PubMed
Summary

Chronic lymphocytic leukemia (CLL), a common leukemia in older adults, remains incurable without transplantation. However, new targeted therapies may soon offer alternatives to standard chemoimmunotherapy for CLL treatment.

More Related Videos

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

13.6K

Related Experiment Videos

Last Updated: Apr 25, 2026

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

23.7K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

13.6K

Area of Science:

  • Hematology
  • Oncology
  • Cancer Biology

Background:

  • Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults, primarily affecting the elderly.
  • Current standard treatment involves chemoimmunotherapy, but it is often insufficient for a cure.
  • Allogeneic transplantation is curative but limited by toxicity and donor availability.

Purpose of the Study:

  • To review the current treatment landscape for CLL.
  • To highlight emerging therapeutic agents targeting key CLL pathways.
  • To discuss the potential shift in the standard of care for CLL management.

Main Methods:

  • Literature review of recent clinical trials and research publications.
  • Analysis of targeted therapies based on their mechanisms of action.
  • Discussion of the clinical implications of novel therapeutic approaches.

Main Results:

  • Chemoimmunotherapy remains the current standard of care for symptomatic CLL.
  • New agents targeting specific molecular pathways in CLL have shown promising results.
  • These novel therapies offer potential for improved efficacy and reduced toxicity.

Conclusions:

  • The treatment paradigm for CLL is evolving with the introduction of targeted therapies.
  • These new agents represent a significant advancement in managing CLL.
  • Future CLL treatment may move beyond traditional chemotherapy towards personalized, targeted approaches.